Left Ventricular Ejection Fraction clinical trials at UCSF
1 research study open to eligible people
Left ventricular ejection fraction is the percent of blood the left ventricle ejects each beat. UCSF is comparing an oral drug to placebo in people with pulmonary hypertension and heart failure with preserved ejection fraction. The study reports on exercise tests and heart measures.
Showing trials for
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
open to eligible people ages 18-85
This study will evaluate the efficacy of TNX-103 (oral levosimendan) compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance (6 MWD; Day 1 to Week 12).
San Francisco, California and other locations
Last updated: